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Abstract: Peri-implant bone loss leading to dental implant failure does not develop in the same
way across subjects who apparently present the same condition—specifically, in the case of Down
syndrome patients with the same genetic disorder—given that they do not necessarily develop
immune–inflammatory disorders to the same extent. Methods: This retrospective case-control study
was aimed at identifying the possible genes involved in implant failure in Down syndrome patients by
matching the periodontal disease variable by means of a retrospective case-control study. This process
involved using the functional analysis of gene expression software Transcriptome Analysis Console
(TAC, Affymetrix, Thermo Fisher Scientific, Waltham, MA, USA) and a search for the possible
candidate genes involved. Focus was placed on the 92 genes related to the inflammation identified
from the TaqMan™ Array Plate Human Inflammation Kit (Thermo Fisher Scientific, Waltham, MA,
USA). Results: Six genes showed statistically significant results (p < 0.05) in our comparison. Three of
them—PLCG2 (p = 0.0333), ALOX5 (p = 0.03) and LTAH4 (p = 0.0081)—were overexpressed in the
implant reject group, and the following three were down-regulated: VCAM1 (p = 0.0182), PLA2G2A
(p = 0.0034) and PLA2G10 (p = 0.047). Conclusion: Statistically significant differences exist in the
gene expression involved in osteoclastogenesis, inflammatory response and host defensive response.
Keywords: Down syndrome; bone biology; clinical outcomes; gene expression; osseointegration;
periodontal disease; dental implant; systemic disease
1. Introduction
Periodontitis cannot currently be deemed a simple bacterial infectious disease leading to the
destruction of periodontal tissues. Rather, it can lead to a complex network of interactions between
the host inflammatory response, the subgingival microbiota and other systemic and local modifying
factors [1]. For this reason, despite the fact that the changes that occur at the level of the subgingival
microbiota (dysbiosis) are necessary for periodontal disease to develop, they are not sufficient to
justify the disease. This led us to think that individual susceptibility is key in the etiopathogenesis of
periodontal disease.
Today, it is accepted that the accumulation of bacterial plaque represents only 20% of the risk
for the development of periodontal disease [1]. In light of this, current studies need to focus on the
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search for the genes, proteins and metabolites involved in the inflammation-immunity mechanisms
that justify the progression and/or resolution of periodontal disease [2].
We realize that scientific evidence strongly supports the association between bacterial plaque and
peri-implantitis, which the European Federation of Periodontology stated in its 2019 guidelines titled
“Peri-Implant Health, Peri-Implant Mucositis and Peri-Implantitis” [3]. We also know that patients with
a history of periodontal disease have an increased risk of developing peri-implantitis [3]. However,
we proposed the present study with the aim of identifying those genes that may be involved in the
development of peri-implant bone loss leading to dental implant failure in Down Syndrome patients.
We did this because we believed in the existence of an individual susceptibility factor within the same
population that causes some individuals diagnosed with periodontal disease to have implant failure,
whereas others have positive evolutions of the same kind.
Down syndrome is one of the most common human genetic syndromes. According to
the United Nations, it has an incidence of 1/1000 and 1/1100 in newborns. Down syndrome
patients present a large number of diseases that affect practically every system. At the oral level,
we highlight periodontal disease, necrotizing gingivitis, chronic periodontitis and, above all, aggressive
periodontitis. With respect to the latter entity, we sought to identify peculiarities with respect to
the periodontopathogens and inflammation mechanisms present in patients with Down syndrome.
Despite the fact that an increase has been observed in certain bacteria, such as Porphyromonas
gingivalis (Pg) and Aggreggatibacter actinomycentencomitans (Aac), among others, the host response,
immune–inflammatory alteration, seems to be the main cause of the development of the entity [4,5].
Alterations of immunity are well known in patients with trisomy 21.
Dental rehabilitation is necessary for those suffering from periodontal disease. In certain
circumstances, the placement of dental implants is the only therapeutic option [4,5]. A patient
may be selected to be an implant candidate based on factors such as the patient’s macroglossia, alveolar
bone quality, poor collaboration with the treatment, tendency to develop an infection and difficulty
in maintenance.
In this sense, very few case-control studies showed the results of the placement of dental implants
in patients who have Down syndrome, as we argued in our earlier-published article [4]. However,
Corcuera et al.’s study [6] is a notable exception given that it demonstrates how implant placement in
these patients can have very adverse results. Nonetheless, the prognosis for implants in this patient
category is fairly poor.
In this study, we wished to identify the genes that may be involved in the development of
peri-implant bone loss by comparing two groups of Down syndrome patients with periodontal disease.
One of them included patients with implant loss after two years (PD+ IR+), whereas the other group of
patients presented positive implant outcomes during assessments after two years (PD+ IR-). Focusing
on a gene expression study, we took as a reference the 92 genes related to inflammation that were
identified using the quantification of ribonucleic acid (RNA) samples from six Down syndrome children.
We also used the TaqMan™ Array Plate Human Inflammation Kit (Thermo Fisher Scientific, Waltham,
MA, USA) used in the study by C.R. Silva, J.M. Biselli-Périco, B.L. Zampieri, et al. [7].
2. Experimental Section
This retrospective case-control study received approval from the Ethics Committee of the Virgen
del Rocío University Hospital, Seville (Exp PI-0081-2016). The patients or their guardians provided
their consent because the benefits obtained from the study directly impacted the patients taking part in
the research. The study was descriptive and observational, as the only invasive procedure performed
on each patient is the collection of a small amount of blood and a dental examination.
2.1. Sample and Groups
The two study groups were made up of Down syndrome patients diagnosed with periodontal
disease (PD); the first group (1) also presented implant rejection (periodontal disease plus implant
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rejection, or PD+ IR+), whereas the second group (2) showed positive assessments of their implants
(PD+ IR-) after two years. The criterion used for determining that a patient was suffering from
periodontal disease is the one that Bassani et al. [8] developed. In accordance with this criterion,
periodontal disease was defined by the presence of three or more teeth with one or more sites with
clinical attachment loss greater or equal to 3 mm, plus the existence of BOP (Bleeding on Probing)
in said sites. It is worth highlighting that during rehabilitation with implants, peri was inactive
(BOP negative), or patients had previously lost all of their teeth. Within the concept of implant rejection,
we included implant failures resulting from a lack of osseointegration, as well as implants that had to
be removed for presenting bone loss greater than 50% of its length in the follow-up period, whether or
not the implants were accompanied by perimplantar infection.
The exclusion criteria used include the following:
- Patients without Down syndrome
- Patients receiving treatment that could have repercussions for bone metabolism
- Patients with untreated periodontal disease
Four patients were included who had periodontal disease and implant rejection compared with
six patients who had periodontal disease and positive implant outcomes, thus leading to a total of
10 patients in the study. Demographic and clinical variables were taken from medical records, with all
essential details used in the verification process.
2.2. Sampling and Total RNA Isolation
At the time of the examination of the patients who were selected and included in this study,
a sample was taken comprising two blood draws from the median cubital vein per person in PAXgene™
(5 mL) tubes (Qiagen N.V., Hilden Germany), reference 762165 (100 tubes), with the final aim of
extracting RNA. The transfer of the samples to the processing center was undertaken in refrigerated
conditions (2–8 ◦C) and never took more than three days.
The extraction of the RNA sample was undertaken using a QIAgen PAXgene Blood miRNA Kit
(Qiagen N.V., Hilden Germany), reference 763134, at an automated QIAcube (Qiagen N.V., Hilden
Germany). Subsequently, a database was created for the samples detailing, inter alia, the RNA
quantification data.
First, RNA concentrations were quantified using visible light spectroscopy with NanoDrop 2000c
equipment (Thermo Fisher Scientific, Waltham, MA, USA) to ensure the correct processing of these
before storage. Second, a much more accurate measurement was taken using fluorescence and Qubit
3.0 equipment (Thermo Fisher Scientific, Waltham, MA, USA) to study gene expression, the results of
which were added to the database.
2.3. Functional Analysis of Expressed Genes
The experimental approach was one of the last steps taken in the study of gene expression to
find candidate genes in metabolic pathways that would be of interest. The GeneChip® Scanner 3000
platform (Thermo Fisher Scientific, Waltham, MA, USA) was selected, and the chips chosen were
Clariom S solutions for a human, mouse and rat, with more than 20,0000 genes annotated for measuring
expression levels (Thermo Fisher Scientific, Waltham, MA, USA).
The RNA selected was amplified and hybridized using the GeneChip® WT PLUS Reagent Kit
(Thermo Fisher Scientific, Waltham, MA, USA). Amplification was performed from an initial total of
55 g and was undertaken in accordance with the manuals in the GeneChip® WT PLUS Reagent Kit
(Thermo Fisher Scientific, Waltham, MA, USA).
Finally, analysis was undertaken by normalizing and using the robust multi-array method.
J. Clin. Med. 2020, 9, 2525 4 of 11
2.4. Statistical Analysis from the 96-Plex Card Genes
An analysis of the various gene expressions was undertaken using Transcriptome Analysis
Console (TAC, Affymetrix, Thermo Fisher Scientific, Waltham, MA, USA) software. Genes that were
used as a reference for the search from the results obtained from our study are the 92 genes related to
the inflammation of the 96-plex gene card (Table 1) that were quantified from the RNA samples of six
Down syndrome children using the TaqMan® Array Plate Human Inflammation Kit (Thermo Fisher
Scientific, Waltham, MA, USA) [7]. Values less than 0.05 were deemed statistically significant and are
the ones shown in this study.
3. Results
3.1. Gene Expression Analyses
Of the 92 genes used as a reference from the above-mentioned study [7], only six showed statistically
significant differential gene expression (p < 0.05) when our two study groups (PD+IR+ vs PD+IR-) were
compared using Transcriptome Analysis Console (TAC, Affymetrix, Thermo Fisher Scientific, Waltham,
MA, USA) software. Three of the genes—PLCG2, ALOX5 and LTAH4—showed up-regulated results,
whereas the VCAM1, PLA2G2A and PLA2G10 genes appeared to be down-regulated (Table 2).
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Table 1. A total of 92 genes related to inflammation, and four reference genes (ª) from the 96-plex gene card [7].
18Sª GAPDHª HPRT1ª GUSBª A2M ADRB1 ADRB2 ALOX12 ALOX5 ANXA1 ANXA3 ANXA5
KLK3 BDKRB1 BDKRB2 CACNA1C CACNA1D CACNA2D1 CACNB2 CACNB4 CASP1 CD40 CD40LG CES1
LTB4R MAPK14 NR3C1 HPGD HRH1 HRH2 HTR3A ICAM1 IL1R1 AL2RA IL2RB IL2RG
IL13 ITGAL ITGAM ITGB1 KTGB2 KLK1 KLK2 KLKB1 KNG1 LTA4H LTC4S MC2R
NFKB1 NOS2 PDE4A PDE4B PDE4C PDE4D PLA2G1B PLA2G2A PLA2G5 PLCB2 PLCB3 PLCB4
PLCD1 PLCG1 PLCG2 MAPK1 MAPK3 MAPK8 PTAFR PTGDR PTGER2 PTGER3 PTGFR PTGIR
PTGIS PTGS1 PTGS2 TBXA2R TBXAS1 TNF TNFRSF1A TNFRSF1B VCAM1 IL1R2 PLA2G7 PLA2G10
PLA2G4C IL1RL1 HTR3B TNFSF13B CYSLTR1 HRH3 PLA2G2D IL1RAPL2 KLK14 PLCE1 KLK15 LTB4R
Table 2. Results of the differentially expressed genes across the two study groups: Down Syndrome Patients with Periodontal Disease and Implant Rejection (PD+IR+),
and Down Syndrome Patients with Periodontal Disease and Positive Outcome of Implants (PD+IR-). (AVG = Average.).
GENE GENE ID - OMIM GENE NAME PD+IR+AVG (Log2)
PD+IR- AVG
(Log2)
PD+IR+
Standard
Deviation
PD+IR-
Standard
Deviation
Fold Change p-Value Chromosome
PLCG2 * 600220 Phospholipase c,gamma-2 12.32 11.85 0.41 0.39 1.39 0.0333 chr16
ALOX5 * 152390 Arachidonate5-lipoxygenase 11.24 10.29 0.6 0.9 1.94 0.03 chr10
LTA4H * 151570 Leukotriene a4hydrolase 14.11 12.76 0.81 0.67 2.55 0.0081 chr12
VCAM1 * 192225
Vascular cell
adhesion
molecule 1
5.51 6.27 0.22 0.48 −1.69 0.0182 chr1
PLA2G2A * 172411 Phospholipase A2,group IIa 3.95 4.74 0.27 0.49 −1.73 0.0034 chr1
PLA2G10 * 603603 Phospholipase A2,group X 5.51 6.02 0.21 0.46 −1.42 0.047 chr16
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None of the genes of PLCG2, ALOX5, LTAH4, VCAM1, PLA2G2A and PLA2G10 showed
statistically significant differential expressions when the study groups were modified into patients with
periodontal disease and implant rejection versus patients without periodontal disease and with positive
evolutions of their implants (PD+IR+ vs. PD-IR-). The study group in our previously published
article [5], and, similarly, genes that were expressed differentially in PD+IR+ versus PD-IR-, ITGB2,
TNFSF13B, ANXA3 and ANXA5 did not show any alterations in the new comparison of this study
(PD+IR+ vs. PD+IR-). This leads us to think that, when it comes to matching the periodontal disease
suffering variable, the genes most closely related to its development were expressed in similar fashions
in both study groups, thus highlighting the genes involved in other metabolic pathways. This might
explain why one group experiences implant failure but the other does not, even though they both
suffer from periodontal disease.
3.2. Functional Analyses of Differentially Expressed Genes
The six genes that showed statistically significant differential expressions were analyzed using the
Online Mendelian Inheritance in Man® (OMIM) database (Johns Hopkins University, Baltimore, MD,
USA), an online catalog on human genes and genetic disorders, and the information was completed
using data available in the Kyoto Encyclopaedia of Genes and Genomes (KEGG), as well as the
literature available in PubMed (Table 3).
Of the six genes, only PLCG2 directly takes part in the osteoclastic differentiation pathway.
However, it does not appear to be the only gene that codifies a molecule involved in osteoclastogenesis,
as ALOX5 and LTA4H seem to be involved in inducing the formation of osteoclasts mediated by
RANKL and other pathways, such as MAPK and NF-kB, which is argued later.
On the other hand, VCAM1, PLA2G2A and PLA2G10, down-regulated genes, maintain, amongst
other functions, close relationships with the defensive host response in the face of bacterial infection,
inflammation and immune response regulation/suppression situations.
Table 3. Metabolic pathways in which each of the genes takes part with statistically significant results
in our study. In the pathways column, only the pathways that are of interest in this study have been
shown. The rest of the pathways in which the genes take part may be found at https://www.kegg.jp.
GENE PATHWAYS (KEGG) p-VALUE FOLD CHANGE
PLCG2
ko04020 Calcium signalling pathway
0.0333 1.39ko04064 NF-kappa B signalling pathway
ko04380 Osteoclast differentiation
ALOX5
ko00590 Arachidonic acid metabolism
0.03 1.94ko01100 Metabolic pathways
LTA4H
ko00590 Arachidonic acid metabolism
0.0081 2.55ko01100 Metabolic pathways
VCAM1
ko04064 NF-kappa B signalling pathway
0.0182 −1.69ko04514 Cell adhesion molecules (CAMs)ko04668 TNF signalling pathway
ko04670 Leukocyte transendothelial migration
PLA2G2A
hsa00564 Glycerophospholipid metabolism
0.0034 −1.73
hsa00565 Ether lipid metabolism
hsa00590 Arachidonic acid metabolism
hsa00591 Linoleic acid metabolism
hsa00592 alpha-Linolenic acid metabolism
hsa01100 Metabolic pathways
PLA2G10
hsa00564 Glycerophospholipid metabolism
0.047 −1.42
hsa00565 Ether lipid metabolism
hsa00590 Arachidonic acid metabolism
hsa00591 Linoleic acid metabolism
hsa00592 alpha-Linolenic acid metabolism
hsa01100 Metabolic pathways
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4. Discussion
In this study, we attempted to discover the underlying reason for the high rate of implant failure
that we found in Down syndrome patients. This is important given that, on occasion, the only
therapeutic option we have for rehabilitating occlusion and therefore improving their quality of life is
the placement of dental implants.
In the article that our study group published earlier [5], the conclusion reached was that despite that
both groups suffered from the syndrome, patients who were diagnosed with periodontitis presented
certain degrees of individual susceptibility stemming from the differential expressions of genes such as
TNFSF13B, ITGB2, ANXA5 and ANXA3, as well as their involvement in immune and/or inflammatory
disorders. This supports the fact that even though they are individuals with the same genetic disorder,
they do not necessarily develop inflammatory disorders, such as periodontitis, to the same degree.
Now let us take one step further: just as periodontal disease develops in different degrees of
severity in individuals who apparently share the same condition, why do some patients who present,
by definition, disorders in the immune–inflammatory system, such as Down syndrome, present implant
failure whereas others maintain functionality?
Considering the above, in this study, the comparison of groups was decided in which all individuals
that presented active periodontal disease or clear signs of disease affecting peri-implant health in the
case of edentulous patients, two years after the diagnosis of the implant failure or positive implant
outcome. Of the 92 genes related to inflammation that are presented in the 96-plex card gene [7], only
six genes provided statistically significant (p < 0.05) results.
Phospholipase C gamma 2 (PLCG2) is the only gene in our results that showed direct involvement
in osteoclast differentiation. PLCG2 was overexpressed in the implant rejection group with p < 0.033.
PLCG2, the protein codifying the gene, regulates the route of osteoclastogenesis through its interaction
with proteins ITAM and GAB2. Its elimination results in an in vivo osteopetrotic phenotype in mice
through the incapacity to form mature osteoclasts, without any difference with respect to osteoblasts
and the rate of bone formation or mineral apposition [9] observed. This then leads us to understand
that it is an intrinsic defect in the osteoclast lineage. We realize that PLCG2 elimination can result
in an osteopetrotic phenotype [9,10] with an increase of more than three times the percentage of
trabecular bone volume, a smaller number of osteoclasts per bone perimeter, and a larger number of
bone trabeculae, as well as those that are larger in thickness with less space between them. Provided
that we are talking about an increase in PLCG2, as is the case in our results, we could speculate
about an opposite situation and therefore a possible explanation for peri-implant bone loss by the
osteoporotic phenotype. Furthermore, this is supported by the fact that a mutation in PLCG2
provokes an augmented and sustained response from calcium [11], which perpetuates the activation
of NFATc1 [10,12,13], a key transcription factor for the expression of specific osteoclast genes. In our
results, greater osteoclastogenesis could be justified by an increase in NFATc1 activation as a result of a
greater flow of calcium sustained by a greater expression of PLCG2.
In addition, PLCG2 takes part in the NF-kB signalling pathway, specifically in the B cell receptor
signalling pathway (BCR). Changes in this pathway result in stronger BCR signals due to increased
calcium responses, with a direct impact on the development of B cells, which can lead to a breakdown
in tolerance [11]. Therefore, we might be led to believe that overexpression in our results for PLCG2
would give rise to an osteoporotic phenotype through direct participation in osteoclastogenesis.
However, we would also be talking about an impaired inflammatory situation characterized by severe
inflammation and autoimmunity, through an increase in B cell activity. This, in turn, would amplify
osteoclast recruitment at the inflammation site.
Likewise, macrophage inflammatory proteins (MIP) take part in osteoclast recruitment and
development at bone resorption sites. Specifically, MIP-1D increases the phosphorylation of PLCG2
and therefore its activity [12]. Consequently, again, we highlight this enhanced osteoclastogenesis
response not only through the inherent overexpression of PLCG2 but also through the direct action of
other cytosines, such as MIP-1D.
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ALOX5, Lipoxygenase-5 and LTA4H, LTA4 Hydrolase, are jointly analyzed because they form
part of the same pathways. The main function of ALOX5 is to transform fatty acids, such as arachidonic
acid (AA), into leukotrienes, specifically into Leukotriene A4. LTA4H, in short, transforms LTA4 into
LTB4, Leukotriene B4. It is well known that leukotrienes play an important role in inflammation,
and one of the actions attributed to LTB4 is inhibition in bone formation and stimulation in bone
resorption [14]. In our results, not only is ALOX5 overexpressed but also LTA4H is overexpressed.
Therefore, we are talking about a joint increase in LTA4 and LTB4.
In a study [14], it was observed that when it came to inhibiting ALOX5, RANKL-induced osteoclast
formation was inhibited without causing cell toxicity. The prevention of osteoclast formation and
LPS-induced bone resorption lacunae [14,15] is shown in vivo. One can observe an improvement
through the restoration of mineral bone density; an increase in trabecular bone volume; and a greater
trabecular thickness, number and separation. In our results, not only was ALOX5 overexpressed,
but we also encountered a situation in which LPS was present given that periodontitis predominantly
presents microbiota of Gram-negative bacteria. This is an unfavorable situation because it has a gene
that seems to boost osteoclast activity. In addition, bacterial action drives the latter.
As mentioned earlier, the expression of NFATc1 is decisive for osteoclastogenesis. Its regulation
may occur via the calcium signalling pathway, where, in our results, PLCG2 was overexpressed.
Its regulation may also occur via the MAPK and NF-kB pathways, where the literature supports the
influence of ALOX5 on NFATc1 expression [15]. Consequently, if our results showed that ALOX5
was also overexpressed, we could say that there was a greater expression and therefore activation of
NFATc1 through all of the possible osteoclastogenesis pathways.
Similarly, LTB4, which is considered to be the most pro-inflammatory metabolite of ALOX5 [16],
is obtained from LTA4 through the action of LTA4 hydrolase (LTA4H), a gene that was also overexpressed
in our results. LTA4H takes part in chemotaxis, the production of reactive oxygen species, and in the
production of IL1, IL6 and IFNG. LTB4 is augmented in crevicular fluid and in the saliva of patients with
periodontal disease [16], and it is associated with a greater level of severity of the disease [17]. Likewise,
it has been related to improvement in the differentiation and activity of osteoclasts that negatively
affect bone turnover without the need to increase the number of osteoclasts. It has also been related to
reducing the differentiation and activity of osteoblasts, as well as improving the calcium flow [16–19].
This is supported by ALOX5 inhibition [16,17], where the inhibition of bone resorption has been
observed via a significant reduction in the number of osteoclasts, as well as a decrease in the severity
of the inflammation, due to a significant reduction in the number of polymorphonuclear (PMN) and
mononuclear cells. This is associated with a discreet increase in IL-10, an anti-inflammatory cytokine,
probably due to a lower level of the production of LTB4 [16], even in the presence of an infection with
Aggregatibacter actinomycetemcomitans [17]. In our results, LTA4H was overexpressed, which could be
understood as an increase in LTB4 in PD+IR+ patients compared with PD+IR-. This is associated with
an increase in resorption at the bone level, as well as a prolonged and marked inflammatory response
at the immune level. With regard to this latter point, it should be emphasized that in patients with
implant rejection, it has been observed that the gene codifying IL-10, an anti-inflammatory cytokine,
is down-regulated.
It appears that all of our findings point to the study patients who presented implant failure
exhibiting prolonged and marked osteoclastogenesis compared with the group presenting positive
implant outcomes. With both groups featuring Down syndrome patients, the groups were faced with
the same underlying genetic condition and the same oral pathological condition. Both groups suffered
from active periodontal disease and therefore chronic inflammation.
Furthermore, VCAM1 is the gene that codifies vascular cell adhesion protein 1, and it mediates
lymphocyte, monocyte, eosinophil and basophil adhesion to the vascular endothelium. Besides taking
part in the signal transduction of leukocyte endothelial cells, it appears to show activity on osteoclasts,
this time through skeletal stem cells. These cells have been defined as specific skeletal stem cells,
deemed necessary for bone development and remodeling. They present potential for inducing
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osteoprotegerin (OPG) expression in inflammatory environments by suppressing osteoclast formation
and therefore bone resorption. They act in synergy with ICAM-1 and VCAM-1, which are necessary for
capturing osteoclast precursors. This enables OPG to work in proximity to the cells to inhibit RANKL,
inter alia [20]. In our results, we observed a lower level of expression of VCAM-1 in the implant
rejection group. We could observe a reduced efficiency of OPG for inhibiting osteoclastogenesis in an
inflammatory environment, as is the case with periodontal disease.
However, osteoclastogenesis is not the only metabolic pathway that seems to be impaired and related
to implant failure in Down syndrome patients. Focusing more on the immune–inflammation response,
VCAM-1 is deemed important in mesenchymal stem cell (MSC)-mediated immunosuppression. This is
because for MSCs to exert their powerful immunosuppressant activity through NO production in the
mouse immune system, lymphocytes must be close to the MSCs. Curiously, in the human immune
system, MSCs used indoleamine 2,3-dioxygenase (IDO) instead of NO to suppress the immune response
and the cell–cell contact mediated by the adhesion molecules necessary for immunosuppression [21].
If we observed down-regulated VCAM-1 in our results, one might consider an inflammatory response
perpetuated by lower T-cell-mediated immunosuppression at the inflammation site.
Finally, we focus on PLA2G2A and PLA2G10 genes, which belong to groups II and X of
phospholipase A2, respectively. PLA2G2A codifies type IIa secreted phospholipase A2 (sPLA2-IIA),
which is considered to be a “natural host antibiotic,” as it is an antimicrobial polypeptide [22]. sPLA2-IIa
may act independently against Gram-positive bacteria and is considered to be the most powerful
tool for eliminating this type of bacteria, followed by group X-secreted phospholipase A2 (sPLA-X).
sPLA2-IIA can be used in combination with other defense systems, bactericidal/permeability-increasing
protein (BPI), a complement system, lysozymes, etc. [23,24]. sPLA2-IIA’s concentration increases in
the serum of patients with sepsis, which points to a fundamental role in the immune response [24].
Note that sPLA2-IIA increases its expression after inflammatory stimuli or bacterial invasion. Curiously,
sPLA2-IIA expression increases up to 3900 times when it is exposed to Porphyromonas Gingivalis
(Pg) [24,25], which suggests that Pg acts by directing change in the host microbiota, instead of
inducing inflammation directly. This unleashes a chronic inflammatory response that leads to a greater
destruction of periodontal tissue.
Continuing with the bactericidal properties of sPLA2-IIa and sPLA-X, in humans, it is observed
that group IIa has the greater level of bactericide action, as it is very efficient (it kills  99% of bacteria)
in minimum concentrations (0.5 µg/mL), followed by group X, which kills  99% of bacteria but at
a concentration of 50 µg/mL [26]. If PLA2G2A and PLA2G10 were down-regulated in our results,
greater susceptibility to infections by impaired natural antimicrobial action could be contemplated.
Furthermore, this leads us to think about what PLA2G2A expression and PLA2G10 expression would
be like if we were to compare Down syndrome patients with a non–Down syndrome control group.
Would it be one of the possible causes of susceptibility to infection in patients who suffer from
the syndrome?
We recognize the need for a subsequent study on gene validation to determine the accuracy of the
genetic alterations found, given the sample size.
5. Conclusions
Our study showed how patients with Down syndrome who were diagnosed with active periodontal
disease presented with different evolutions compared with those rehabilitated using dental implants.
Despite the fact that all of the patients in the study suffered from the same genetic disorder and the
same immuno-inflammatory disorder by definition, the study group that showed positive evolutions of
the implants (PD + IR-) seemed to be able to stabilize the lesion, whereas the group with implant failure
(PD + IR +) exhibited differential expressions of genes that participated in the different activation
routes and progression of osteoclastogenesis. This seems to lead to an accelerated loss of peri-implant
bone support directed by the deterioration of the immune–inflammatory response. Therefore, we
could call it a genetically susceptible group that causes the condition to progress and leads to the
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clinical manifestation of peri-implantitis. This leads us to accept that the inflammatory response of the
host drives the pathological process, to a great extent, not only for the periodontal disease but also
for the peri-implantitis. Therefore, it also leads to the understanding that the inflammation of the
periodontal and peri-implant tissues leads to the destruction of local tissue.
Recognizing the importance of being able to modulate the inflammatory response and determining
the patient’s genetic circumstances may represent a new treatment opportunity.
Finally, we note that the differential gene expression studied in this article does not occur in
chromosome 21, which highlights the genetic complexity that underlies Down syndrome.
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